The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...

The FDA is about to make it a lot harder to get cheap weight-loss drugs Jessica DeBenedetto has only been on compounded tirzepatide for a couple of weeks, but she already feels like it's a life ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...

The FDA has approved tirzepatide for diabetes and weight management. To get an online tirzepatide prescription, you’ll need ...

The FDA announced that the tirzepatide injection shortage is resolved. Hims & Hers Health, Inc.'s stock fell 6.90%, reflecting market concerns over regulatory updates and supply chain stability.

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

Weight-loss injection Mounjaro, also known as tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this year, but many eligible patients will have to wait.

Tirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says. Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025 ...